Skip to main content

Auction result of Treasury Bonds – RIKB 38 0215 – RIKS 29 0917

Series  RIKB 38 0215 RIKS 29 0917Settlement Date  07/22/2026 07/22/2026Total Amount Allocated (MM)  4,510 1,350All Bids Awarded At (Price / Yield)  96.725 / 6.910 99.725 / 3.591Total Number of Bids Received  23 5Total Amount of All Bids Received (MM)  5,310 1,350Total Number of Successful Bids  19 5Number of Bids Allocated in Full  19 5Lowest Price / Highest Yield Allocated  96.725 / 6.910 99.725 / 3.591Highest Price / Lowest Yield Allocated  97.000 / 6.880 99.810 / 3.562Lowest Price / Highest Yield Allocated in Full  96.725 / 6.910 99.725 / 3.591Weighted Average of Successful Bids (Price/Yield)  96.803 / 6.900 99.738 / 3.586Best Bid (Price / Yield)  97.000 / 6.880 99.810 / 3.562Worst Bid (Price / Yield)  96.420 / 6.950 99.725 / 3.591Weighted Average of All Bids Received (Price / Yield)  96.776 / 6.910 99.738 / 3.586Percentage...

Continue reading

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees. The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to quarterly vesting dates of February 15, May 15, August 15 and November 15 (the “Quarterly Vesting Dates”). For each new employee, 25% of the Inducement Grant will...

Continue reading

Camping World Holdings, Inc. to Announce Second Quarter 2026 Earnings on July 29, 2026, with a Call Premarket on July 30, 2026

LINCOLNSHIRE, Ill., July 17, 2026 (GLOBE NEWSWIRE) — Camping World Holdings, Inc. (NYSE: CWH) (the “Company”) today announced that its financial results for the second quarter 2026 will be released after the market closes on Wednesday, July 29, 2026. The Company will host a conference call on Thursday, July 30, 2026 at 7:30 a.m. Central Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 800-717-1738 (international callers please dial 1-646-307-1865) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at http://investor.campingworld.com. A taped replay of the conference call will be available within two hours of the conclusion of the call and can be accessed both online and by...

Continue reading

Wakefern and ShopRite Expand Edible Garden’s Successful “Garden Starters” Program with Midsummer Promotion

Strong Consumer Response Drives Expanded Seasonal Merchandising Initiative Across Participating ShopRite Locations BELVIDERE, N.J., July 17, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that Wakefern Food Corp. is expanding the Company’s Garden Starters pallet display program with a new midsummer promotional event across participating ShopRite locations. Building on strong customer response during the spring season, the expanded promotion is designed to meet continued consumer demand for fresh, living herbs while encouraging home gardening and outdoor entertaining throughout...

Continue reading

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: “At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secretary Kennedy is looking to transform treatment opportunities through the expansion of new therapeutic approaches.” This week’s developments include...

Continue reading

42/2026・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities

Schindellegi, Switzerland – 17 July 2026 Trifork Group AGCompany announcement no. 42/2026 Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation Article 19, Trifork Group AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork or persons closely associated with them.1. Details of the person discharging managerial responsibilities/person closely associateda) Name Anja Monrad2. Reason for the notificationa) Position/status Chairperson of the Board of Directorsb) Initial notification/Amendment Initial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction...

Continue reading

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responsesCOPENHAGEN, Denmark, July 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27,...

Continue reading

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in vision and retinal...

Continue reading

BrewDog and Tilray Brands Unlock £1 Million Bar Tab for Football Fans Across England, Scotland and Ireland

BrewDog and Tilray are keeping football’s biggest celebration alive by unlocking the £1 million bar tab at participating pubs1 beginning July 20 because great football deserves celebrating, no matter who lifts the trophyLONDON and ELLON, Scotland, July 17, 2026 (GLOBE NEWSWIRE) — Leading UK craft beer brand and Scottish brewer BrewDog, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced that this celebration is for the fans. BrewDog and Tilray Brands will continue bringing football supporters together with watch parties throughout the tournament and will keep the celebration going after the final whistle by kicking off the £1 million bar tab at participating BrewDog pubs beginning July 20, 2026. Running through September 30, 2026, the bar tab gives fans across England, Scotland and Ireland more reasons to come...

Continue reading

MoonFox Alternative Data Expands Offline Foot Traffic Coverage to Leading China and Global Stocks

SHENZHEN, China, July 17, 2026 (GLOBE NEWSWIRE) — MoonFox Data, China’s leading alternative data provider, is proud to announce a major expansion of its offline (foot traffic) data coverage, now tracking real-world consumer flows for a new cohort of high-impact listed companies across A-shares, Hong Kong, and US markets. This enhancement further cements MoonFox’s position as the definitive source for actionable China data, empowering global institutional investors with unparalleled visibility into the operational pulse of the world’s fastest-growing consumer economy. Key Highlights:Expanded Universe: MoonFox’s offline dataset now covers 300+ additional stocks, including top A-share names, Hong Kong blue chips, and select US-listed Chinese and global consumer brands. Sector Breadth: Newly added coverage spans core consumer-facing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.